Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.91% Nasdaq Up0.87%

More On PBMD

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates
  • Research Reports

Ownership

Financials


Prima Biomed Ltd. (PBMD)

-NasdaqGM

2.24 0.00(0.00%) Jun 13

Add to Portfolio
ProfileGet Profile for:
Prima Biomed Ltd.
151 Macquarie Street
Level 7
Sydney, NSW 2000
Australia - Map
Phone: 61 2 9276 1224
Fax: 61 2 9276 1284
Website: http://www.primabiomed.com.au

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Prima BioMed Ltd, a biotechnology company, engages in the research and commercialization of licensed medical biotechnology products in Australia. It develops oncology therapies in the field of immunotherapy. The company’s lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. It also manufactures mannosylated fusion protein, a critical component to CVac that contains the antigen necessary for the dendritic cells to illicit an immune response against tumor cells. In addition, the company focuses on developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd is based in Sydney, Australia.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Prima Biomed Ltd.
Key Executives 
 PayExercised
Mr. Matthew Lehman , 36
Chief Exec. Officer, Managing Director and Director		254.00KN/A
Mr. Marc Voigt , 40
Chief Financial Officer, Chief Bus. Officer and Gen. Mang. of German Subsidiary		171.00KN/A
Dr. Sharron Gargosky , 49
Chief Technical Officer		298.00KN/A
Dr. Neil Frazer M.D., Ch.B., FRCA, FFPM, 57
Chief Medical Officer		263.00KN/A
Ms. Deanne Miller LLB,
Gen. Counsel and Company Sec.		N/AN/A
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.